Legend's CAR-T hit 100% response before its FDA clearance

Legend Biotech's LB2501 is an in vivo CAR-T therapy. It's an injection that reprograms a patient's own immune cells to fight cancer, without removing them first. In a first-in-human China trial, reported in June, it hit a 100% response rate in 12 lymphoma patients. On Oct. 17, the FDA cleared Legend to start testing LB2501 in the U.S. too.

Standard CAR-T therapy already works, but it's brutal to deliver. Doctors remove a patient's cells, engineer them in a lab, then grow them back up. That alone can take weeks, and only a few specialized hospitals can do it. LB2501 skips all of that with a single injection. The China results are genuinely striking: every patient responded, and most had no detectable cancer left. But 12 patients is a small group. Bigger trials, including the new U.S. one, will show whether that success rate holds up.

Keep reading — what to watch

Will LB2501 still look this good in a larger trial? Early cancer results have a habit of looking better than they turn out to be. Small trials can get lucky with which patients enroll. Legend hasn't said how many patients the new U.S. trial will include, or when the first one will be dosed.